White-label polygenic risk scores, end-to-end kit fulfillment, and a developer-ready API. Your brand. Your members. Your data.
Trusted by researchers and platforms
The difference genetics makes
A common lipid panel can look only mildly abnormal. A coronary artery disease PRS can reveal when the same result sits on top of elevated inherited risk.
LDL cholesterol is elevated.
Recommend lifestyle review, repeat testing, and treatment decisions based on age, blood pressure, and calculated risk.
Borderline LDL sits on top of high inherited coronary risk.
Use the elevated PRS result to prioritize earlier prevention planning, provider review, and tighter cardiometabolic follow-up.
The platform
A complete stack, from kit fulfillment to API delivery, purpose-built for health platform partners.
The technology
We are deliberately anchored to low-pass whole genome sequencing at 0.5x coverage, imputed to 70+ million variants, delivering genome-wide data at $50 per test. For polygenic conditions, PRS performance is equivalent to 30x. For many common monogenic traits, accuracy is comparable too. 30x is priced for research labs and clinical diagnostics. At $50, a genetic baseline becomes something every member can have.
| lpWGS (Gencove) | Array genotyping | 30x WGS | |
|---|---|---|---|
| Coverage | Entire genome, imputed to 70M+ variants | Pre-selected ~500k-2M sites only | Entire genome at high depth |
| PRS performance | Equivalent to 30x for polygenic conditions | Reduced, limited to array sites | Equivalent to lpWGS for polygenic conditions |
| Ancestry performance | Strong across diverse populations | Optimised for European ancestry | Strong across diverse populations |
| Future-proofing | New insights from existing data. No retesting. | Locked to chip design. May require retesting. | New insights computable. No retesting. |
| Price per member | ~$50 | ~$50-$100 | $699-$1,499+ |
| Clinically validated? | eMERGE framework: formal risk thresholds for 9 conditions | Varies; many lack formal clinical thresholds | CLIA lab ≠ clinical validation. Requires physician interpretation. |
| Best for | Consumer health platforms at scale | Ancestry and basic wellness traits | Research, rare variant detection, clinical diagnostics |
Note: 30x sequencing at a CLIA-accredited lab is not the same as a clinically validated test. Clinical validation requires the assay, pipeline, variant class, and interpretation workflow to be validated for the specific claim being made.
Enabling discovery
As your member base grows, genome-wide data enables your team to build insights no competitor can replicate, without ever asking a member to retest.
As your member base reaches GWAS scale, Gencove's bioinformatics team can help you run novel discovery and build polygenic scores tuned to your own population. Insights your competitors cannot replicate, built on genetics collected at sign-up.
When the science moves (a new GLP-1 pharmacogenomics paper, a new cancer PRS, a newly validated condition), your team can compute new insights from existing member data. The genome is permanent. The value compounds over time.
How it works
Two integration paths. One for new sequencing, one for members who already have genetic data.
Trigger a kit order with a single API call, and Gencove handles fulfillment and shipping. Or let members import existing 23andMe or Ancestry data.
One API call to orderOur CAP and CLIA accredited lab processes the sample at 0.5x coverage and imputes genome-wide data across 70+ million variants. You receive a webhook when results are ready.
Results in 3-4 weeksRetrieve a consumer-ready PRS report with one API call, or use the variant-level API to build your own experience on top of structured JSON data.
One API call for resultsResources
Technical and scientific resources to help your team evaluate, implement, and communicate genetics to members.
A technical comparison of lpWGS, array genotyping, and 30x WGS, covering PRS performance, ancestry, future-proofing, and price.
Request the white paperBased on a Nature paper published in April 2026: GLP1R variants associated with treatment response and side effect risk in 27,885 patients.
Request the case studyPricing
A platform fee covers access, support, and storage. Per-sample fees apply at the time of ordering.